ZVRA — ZEVRA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1434647 ·
Last close
$9.51
Market Cap
$562.18M
52W High
$15.03
52W Low
$9.10
ADV30
1,558,757
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 36,220,000 | 34,323,000 | 8,832,000 | 37,890,000 | 278,579,000 | 95,595,000 | 72,775,000 |
| Dec 2025 | 34,125,000 | 32,605,000 | 9,315,000 | 12,165,000 | 284,731,000 | 62,406,000 | 130,074,000 |
| Sep 2025 | 26,063,000 | 24,825,000 | 4,143,000 | -544,000 | 270,116,000 | 54,439,000 | 136,951,000 |
| Jun 2025 | 25,881,000 | 13,502,000 | -12,329,000 | 74,707,000 | 256,277,000 | 47,712,000 | 139,047,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,598,000
Investing CF
$18,127,000
Financing CF
$12,064,000
CapEx
$-866,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.45
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-422,060,000
Inventory
$1,740,000
Receivables
$23,258,000
ST Investments
$128,605,000
EBIT TTM
$94,655,000
Pretax Income TTM
$86,678,000
Interest Exp TTM
$7,977,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$122,289,000
EBITDA
$12,734,000
Free Cash Flow
$25,852,250
Enterprise Value
$370,400,416
Total Cash
$200,616,000
Total Debt
$1,147,000
Shares Out
59,115,084
Trailing EPS
$2.01
Book Value
$3.48
ROE
100.7%
ROA
2.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 106,470,000 | -4,233,000 | 83,229,000 | 284,731,000 | 130,074,000 | — | -1,598,000 |
| Dec 2024 | 23,612,000 | -87,003,000 | -105,511,000 | 178,127,000 | 138,461,000 | — | -69,665,000 |
| Dec 2023 | 27,461,000 | -49,604,000 | -46,049,000 | 172,327,000 | 110,463,000 | — | -33,535,000 |
| Dec 2022 | 10,161,000 | -24,902,000 | -26,772,000 | 115,340,000 | 40,220,000 | — | -18,717,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$3,695,000
NetIncome TTM
$-33,225,000
OpCashFlow TTM
$0
Assets (Latest)
$178,127,000
Forward EPS
$1.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLMD | RELMADA THERAPEUTICS, INC. | $557.48M | $5.31 | — |
| MPLT | MapLight Therapeutics, Inc. | $554.89M | $13.02 | — |
| ALT | Altimmune, Inc. | $552.31M | $2.84 | — |
| CRMD | CorMedix Inc. | $590.74M | $7.53 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $534.81M | $14.47 | — |
News headlines (Yahoo Finance, 1h cache)
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
2026-07-24 18:43 · Yahoo
Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application
2026-07-24 14:38 · Yahoo
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off?
2026-07-24 12:48 · Yahoo
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
2026-07-24 11:30 · Yahoo
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
2026-07-22 11:30 · Yahoo
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
2026-06-23 11:30 · Yahoo
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
2026-06-11 12:30 · Yahoo
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?
2026-06-09 21:19 · Yahoo
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
2026-06-09 16:50 · Yahoo
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
2026-06-08 18:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.